Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Kodiak Sciences

Explore full profile

Designing and developing novel therapies for the treatment of retinal disease

Palo Alto, United StatesFounded 2009Biotech & Life Sciences
Valuation $6.23B Market cap · 2026

About Kodiak Sciences

Kodiak Sciences Inc. is a biopharmaceutical company focused on researching, developing, and commercializing transformative therapeutics for high prevalence retinal diseases. The company primarily serves patients suffering from conditions such as Wet Age-Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion. Operating within the healthcare and pharmaceutical markets, Kodiak Sciences employs a business model centered on extensive clinical research and development, followed by the commercialization of its proprietary treatments. Revenue is generated through the sale of these therapeutics, which are designed to offer long-term efficacy and safety. The company’s flagship product, KSI-301, has shown promising results in Phase 1b clinical trials, demonstrating durability, efficacy, and safety over a one-year period. Kodiak Sciences aims to address significant unmet medical needs in ophthalmology, leveraging its innovative science to improve patient outcomes.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2009
Headquarters
Palo Alto, United States
Listing
IPO 2018
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tier

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Series B and later1 investor entered at this stage

  • Braidwell
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States88.3%
🇨🇭 Switzerland9.6%
🇨🇦 Canada2.1%
3 countries shown
Web traffic by country
7.3K monthly visits
across markets
🇺🇸 United States76.7%
🇮🇳 India16.4%
🇩🇪 Germany6.8%
Top 3 markets shown

Patents

Estimated portfolio value
$32M

20 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Kodiak Sciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Kodiak Sciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.